Combinations of H3 antagonists and norepinephrine reuptake inhibitors and their applications
By combining an H3 antagonist with a norepinephrine reuptake inhibitor, the release of norepinephrine is regulated, which solves the problem of increased resting arousal and decreased REM sleep in the treatment of arousal disorders in the prior art, and achieves more effective sleep-wake cycle regulation and reduced compound dosage.
Patent Information
- Application Number
- CN201910681199.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-27
- Filing Date
- 2019-07-26
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2039-07-26
AI Technical Summary
In the prior art, the combination of H3 antagonists and norepinephrine reuptake inhibitors showed a superadditive and synergistic effect of significantly increasing resting arousal and reducing REM sleep when treating arousal disorders, but failed to effectively regulate the sleep-wake cycle.
Combinations of H3 antagonists and norepinephrine reuptake inhibitors are used to regulate the release of norepinephrine, enhance resting wakefulness, and reduce REM sleep by simultaneous, separate, or alternating administration. Specific compounds include combinations of H3 antagonists such as teloprecin and norepinephrine reuptake inhibitors such as duloxetine.
It significantly increases resting wakefulness, reduces REM sleep, regulates the sleep-wake cycle, improves treatment efficacy, reduces the amount of compound required, and enhances tolerability.
Smart Images

Figure CN110772515B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to novel compositions and their use in treating arousal disorders in patients with insufficient norepinephrine release. Background Technology
[0002] Wakefulness is controlled by several monoaminergic neuronal systems in the brain, primarily histaminergic and noradrenergic systems, which are active during wakefulness and silent during sleep. Therefore, increased release of histamine or norepinephrine leads to a promotion of wakefulness at the expense of sleep.
[0003] Histamine H3 receptor antagonists / inverse agonists (X. Ligneau et al., Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 365; JSLin et al., Neurobiology of Disease, 2008, 30, 74; RX Guo et al., British Journal of Pharmacology, 2009, 157, 104) are known to regulate sleep / wakefulness with increased arousal.
[0004] WO 2006 / 117609 discloses the H3 ligand, as shown in formula (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide:
[0005]
[0006] In this article, it is referred to as “compound (A)”, and its pharmaceutically acceptable salt, hydrate or hydrated salt.
[0007] Pitolisant The monohydrochloride salt of 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine has become one of the first H3 antagonists / reverse agonists on the market and is currently authorized in Europe for the treatment of narcolepsy with or without cataplexy.
[0008] The effects of H3 antagonists on norepinephrine have been disclosed in AD Medhurst et al. (Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1032-1045), G. Flik et al. (Journal of Molecular Neuroscience, 2015, 56, 320-328), and JSLin et al. (Neurobiology of Disease, 2008, 30, 74-83).
[0009] Antidepressants with norepinephrine reuptake inhibitor properties, such as duloxetine, reboxetine, atoxetine, and venlafaxine (C. Sanchez et al., Pharmacology, Biochemistry and Behavior, 2007, 86, 468), increase wakefulness at the expense of deep sleep and / or REM sleep.
[0010] Kallweit et al. (Expert Opinion on Drug Treatment, vol. 18, no. 8, 2017, pp. 809-817) reported on the pharmacological management of narcolepsy with depression and recommended, for example, venlafaxine.
[0011] Lin et al. (Neurobiology of Disease, vol. 30, no. 1, 2008, pp. 74-83) disclosed the combined use of tiprolisant and modafinil.
[0012] It has now been found that, compared with the effects of administering each compound alone, the combination of H3 antagonists with antidepressants selected from norepinephrine reuptake inhibitors unexpectedly led to a significant increase in resting arousal and a decrease in REM sleep, which were correspondingly enhanced / reduced in a hyperadditive, synergistic manner. Summary of the Invention
[0013] According to the first objective, the present invention therefore relates to a composition of an H3 antagonist or inverse agonist having the following formula and an antidepressant selected from norepinephrine reuptake inhibitors:
[0014]
[0015] In equation (I):
[0016] R 1 It is H or methyl.
[0017] R 2 Is it Cl or The asterisk (*) represents the connection position with the benzene ring.
[0018] n is 0 or 1.
[0019] According to one embodiment, the H3 antagonist / reverse agonist is selected from one of the following compounds:
[0020]
[0021] And any pharmaceutically acceptable salt or solvation thereof.
[0022] More specifically, the H3 antagonist / reverse agonist is Hydrochloride.
[0023] More specifically, the H3 antagonist / reverse agonist is a dihydrochloride. The tetrahydrate of BP1.3656B (here referred to as BP1.3656B).
[0024] According to one embodiment, the compound may be in the form of its free base, or optionally, in the form of a pharmaceutically acceptable salt, such as hydrochloride, oxalate, dihydrochloride, hydrobromide, dihydrobromide, naphthalene-1,5-disulfonate, sulfate, ethane-1,2-disulfonate, cyclamate, toluenesulfonate, p-toluenesulfonate, thiocyanate, nitrate, methanesulfonate, dodecyl sulfate, naphthalene-2-sulfonate, benzenesulfonate, dichloroacetate, glycerol phosphate, 2-hydroxyethanesulfonate, aspartate, maleate, phosphate, ethanesulfonate, camphor-10-sulfonate, glutamate, alginate, dihydroxynaphthyl salt, 2-oxoglutaric acid, 1-hydroxy-2-naphthylcarboxylate, malonate, gentianate, salicylate, tartrate, fumarate, galactose. Citrate, glucuronide, lacturonide, 4-aminosalicylate, glycolate, sesgalactonide, glucohepanoate, pyroglutamate, mandelate, malate, hippurate, formate, gluconate, lactate, oleate, ascorbate, benzoate, succinate, 4-acetaminobenzoate, glutarate, cinnamate, adipate, sebate, camphorate, acetate, hexanoate, nicotinate, isobutyrate, propionate, decanoate, caprylate, hexanoate, laurate, palmitate, stearate, undecene-10-valerate, caprylate, orotate, carbonate, 5-sulfosalicylate, 1-hydroxy-2-naphthylcarboxate, 3-hydroxy-2-naphthylcarboxate; and / or solvates such as hydrates, ethanolates, and semi-ethanolates.
[0025] Therefore, unless otherwise stated, the term "compound" as used herein also refers to its pharmaceutically acceptable salt and / or the solvate thereof.
[0026] According to one embodiment, the antidepressant is selected from duloxetine, reboxetine, atoxetine, desipramine, venlafaxine, norvenlafaxine, and more particularly duloxetine. According to one embodiment, the antidepressant is not venlafaxine.
[0027] According to one embodiment, the antidepressant is a norepinephrine reuptake inhibitor selected from duloxetine, reboxetine, atoxetine, desipramine, and desvenlafaxine, particularly duloxetine, reboxetine, atoxetine, and desipramine.
[0028] According to one implementation method
[0029] The H3 antagonist / reverse agonist is selected from one of the following compounds:
[0030]
[0031] and any pharmaceutically acceptable salts or solvates thereof; and
[0032] The norepinephrine reuptake inhibitor is selected from duloxetine, reboxetine, and atoxetine.
[0033] According to one embodiment, the composition is A combination of HCl (teloliden) and duloxetine.
[0034] According to another objective, the present invention also relates to pharmaceutical compositions comprising the compositions according to the invention, wherein the two components are administered simultaneously, separately, or alternately over time.
[0035] According to another objective, the present invention also relates to the use of the compositions of the invention in the treatment and / or prevention of diseases selected from excessive daytime sleepiness, substance abuse disorders such as alcoholism, and / or attention and cognitive deficits in patients with insufficient norepinephrine release.
[0036] The identification of subjects requiring treatment for the diseases and conditions described herein is entirely within the competence and knowledge of those skilled in the art. Clinicians in this field can readily identify subjects requiring such treatment through the use of clinical tests, physical examinations, genetic testing, and medical / family history.
[0037] According to one embodiment, the disease is excessive daytime sleepiness and occurs in patients suffering from the following conditions:
[0038] - Narcolepsy with or without cataplexy,
[0039] - Idiopathic hypersomnia,
[0040] - Daytime narcolepsy
[0041] -Obstructive sleep apnea,
[0042] -Circadian rhythm sleep-wake disorder
[0043] - Parkinson's disease, or
[0044] Prader-Willi Syndrome.
[0045] According to another implementation, the disorder is an attention and cognitive deficit, and occurs in patients with attention deficit hyperactivity disorder (ADHD).
[0046] According to another alternative implementation, the disease is excessive daytime sleepiness, attention and cognitive deficits, and occurs in patients with depression.
[0047] According to another alternative implementation, the disease is selected from substance abuse withdrawal syndrome.
[0048] It should be noted that alternative implementation methods are not mutually exclusive, but can be considered in combination.
[0049] The actual dose level of a compound can be varied to obtain the amount of active ingredient required to achieve a therapeutic response for a particular composition and method of administration. Therefore, the chosen dose level depends on the desired therapeutic effect, route of administration, required duration of treatment, and other factors such as the patient's condition.
[0050] As can be readily determined by those skilled in the art using conventional techniques and by observing results obtained under similar conditions, the attending physician can readily determine the effective therapeutic dose. In determining the effective therapeutic dose, the attending physician considers numerous factors, including but not limited to: the type of subject; the subject's size, age, and general health condition; the specific disease involved; the extent or severity of the disease; the individual subject's response; the specific compound administered; the route of administration; the bioavailability characteristics of the administration formulation; the chosen dosage regimen; the use of concomitant medications; and other relevant circumstances.
[0051] The amount of compound required to achieve the desired biological effect will vary depending on many factors, including the type of drug formulation to be administered, the type of disease, the patient's disease state, and the route of administration.
[0052] Generally, the preferred dose of a drug to be administered may depend on factors such as the type and extent of disease or symptom progression, the overall health status of the specific patient, the relative bioavailability of the selected compound, the formulation of the compound excipients, and the route of administration.
[0053] The daily dose of an H3 antagonist / inverse agonist (I) is typically 1 μg to 50 mg per patient per day. For illustration, the preferred dose of telolide is 5-40 mg / day, more preferably 10-30 mg / day, and the preferred dose of BP1.3656B is 1-100 μg / day, more preferably 5-30 μg / day.
[0054] The daily dose of antidepressants is typically 2 mg to 250 mg per patient. Examples of dosages are detailed below:
[0055] Desipramine: 10-300 mg / day, preferably 25-200 mg / day; Duloxetine: 20-120 mg / day, preferably 30-60 mg / day; Venlafaxine: 35-375 mg / day, preferably 35-225 mg / day; Desvenlafaxine: 50-400 mg / day, preferably 50-100 mg / day; Atoxetine: 10-100 mg / day, preferably 10-60 mg / day; Reboxetine: 2-12 mg / day, preferably 2-8 mg / day.
[0056] According to another embodiment, the method of the present invention further includes administering one or more other active ingredients selected from anti-Parkinson's drugs, such as levodopa, ropinirole, ergotamine, bromocriptine, pramipexole, or selected from antinarcolepsy drugs or claimed to be from another class of antinarcolepsy drugs, including modafinil.
[0057] Compounds can be formulated into identical or different pharmaceutical compositions by mixing with one or more pharmaceutically acceptable excipients.
[0058] The composition can be conveniently administered in unit dosage form and can be prepared by any method known in the pharmaceutical field, for example, Remington: The Science and Practice of Pharmaceuticals, 20th edition; Gennaro, AR, Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000.
[0059] The compound can be administered via various routes of administration, such as oral; parenteral, including subcutaneous, intramuscular, intravenous; sublingual, local; local; tracheal; intranasal; transdermal or rectal, in combination of the active ingredient with a pharmaceutically acceptable excipient or carrier in one or two pharmaceutical compositions.
[0060] In particular, formulations suitable for parenteral administration are sterile and include emulsions, suspensions, aqueous and non-aqueous injectable solutions, which may contain suspending agents and thickeners, as well as antioxidants, buffers, antibacterial agents, solutes to make the formulation isotonic, and a pH appropriately adjusted with the blood of the intended recipient. For topical administration, the compositions of the present invention can be used as creams, gels, ointments or lotions.
[0061] According to the invention, compounds (I) or compositions are advantageously administered orally in suitable formulations. Formulations suitable for oral administration to patients include discrete units, such as capsules, soft or hard gelatin, tablets, each containing a predetermined amount of a compound of formula (I). They also include powders; granules; solutions or suspensions in aqueous or non-aqueous liquids, or oil-in-water or water-in-oil emulsions. Gastrointestinal resistance agents are also suitable for oral formulations, particularly duloxetine.
[0062] "Pharmaceutical acceptable" or "pharmaceuticalally acceptable" means a molecular entity or composition that, when properly administered to an animal or human, does not produce adverse, allergic, or other adverse reactions.
[0063] As used herein, "pharmaceuticalally acceptable excipients, solvents, or carriers" specifically includes diluents, adjuvants, excipients, or carriers. The use of these components in the active pharmaceutical ingredient is well known in the art.
[0064] In the context of this invention, as used herein, the term “treating” or “treatment” means to reverse, alleviate, or inhibit the progression of a disease or condition to which the term applies, or one or more symptoms of such a disease or condition, or to prevent the disease or condition to which the term applies, or one or more symptoms of such a disease or condition.
[0065] "Therapeutic effective amount" refers to the amount of the compound / drug of this invention that effectively produces the desired therapeutic effect.
[0066] According to the present invention, the term "patient" or "patient in need" is intended for use in humans or non-human mammals who have or may have the aforementioned diseases. Preferably, the patient is a human.
[0067] The compound can be administered in unit dose form, wherein the term "unit dose" refers to a single dose that can be given to a patient and can be easily handled and packaged to remain physically and chemically stable, including the active compound itself, or as one or both pharmaceutically acceptable combinations.
[0068] Suitable unit dosage forms include oral; sublingual, oral, tracheal, intraocular, nasal; by inhalation, local, transdermal, subcutaneous, intramuscular or intravenous, rectal and implantable forms. Attached Figure Description
[0069] Figure 1A The changes in drug-induced sleep-wake balance in rats during the duration of resting wakefulness within 12 hours following administration of teloratesen and duloxetine are represented as mean ± SEM of 15 to 16 individual values.
[0070] Figure 1B The changes in drug-induced sleep-wake balance in rats during REM sleep duration within 12 hours following administration of teloratesen and duloxetine are represented as mean ± SEM of 15 to 16 individual values.
[0071] Figure 2A The changes in drug-induced sleep-wake balance in rats during the duration of resting wakefulness within 12 hours after administration of compound BP1.3656B and duloxetine are represented (mean ± SEM of 15 to 16 individual values).
[0072] Figure 2B The changes in drug-induced sleep-wake balance in rats during REM sleep duration within 12 hours after administration of compound BP1.3656B and duloxetine are represented (mean ± SEM of 15 to 16 individual values).
[0073] Figure 3AThe changes in drug-induced sleep-wake balance in rats during the duration of resting wakefulness within 12 hours following administration of teloristine and reboxetine are represented as mean ± SEM of 15 to 16 individual values.
[0074] Figure 3B The changes in drug-induced sleep-wake balance in rats during REM sleep duration within 12 hours following administration of teloristine and reboxetine are represented as mean ± SEM of 15 to 16 individual values.
[0075] Figure 4A The changes in drug-induced sleep-wake balance in rats during the duration of resting wakefulness within 12 hours following administration of teloratesen and atomoxetine are represented as mean ± SEM of 15 to 16 individual values.
[0076] Figure 4B The changes in drug-induced sleep-wake balance in rats during REM sleep duration within 12 hours following administration of teloratesen and atomoxetine are represented as mean ± SEM of 15 to 16 individual values.
[0077] Figure 5 The expression represents the drug-induced increase in norepinephrine release relative to basal release in the prefrontal cortex of rats after administration of telotrienol and duloxetine (based on AUC within 150 minutes after administration) (mean ± SEM of 6 to 9 individual values). Detailed Implementation
[0078] Example
[0079] Example 1: Effects on sleep / wake cycle
[0080] The effects on sleep / wake parameters were investigated in male Wistar rats. Briefly, rats were stereotactically implanted with cortical electrodes using a telemetry system (Data Science International, St. Paul, Minnesota, USA) for electroencephalography (EEG) recording to acquire, transfer, and store motor activity and EEG signals. EEG signals were analyzed after a Fast Fourier Transform (FFT) of an 8-second duration EEG period, following a procedure adapted from an algorithm proposed by R.P. Louis et al. (Journal of Neuroscience Methods, 2004, 133, 71-80) and an analysis of the vigilance phases according to H. Kleinlogel (Neuropsychobiology, 1990-91, 23, 197-204). This allowed for the identification of each period of its vigilance phase (i.e., active wakefulness, resting wakefulness, light or deep slow-wave sleep, and REM sleep, also known as paradoxical sleep). Rats were orally (orally) administered a carrier, drug, or combination of drugs approximately 30 minutes before the onset of light exposure. EEG signals were then continuously recorded and further integrated over a 12-hour diurnal cycle.
[0081] The effects of single or combined drugs on sleep / wake in rats are shown in the table below. Figure 1A and Figure 1B (Teloliden / duloxetine) Figure 2A and Figure 2B (BP1.3656B / duloxetine) Figure 3A and Figure 3B (Telolide / Reboxetine) and Figure 4A and Figure 4B (Telolizan / Tomoxicillin):
[0082] In the case of the telorazole / duloxetine combination, the combination showed a 35% increase in resting wakefulness compared to a cumulative increase of +19%. Furthermore, when the two compounds were used in combination, the reduction in REM sleep induced by duloxetine was enhanced (-35% vs. -23%), while telorazole itself had no significant effect after 12 hours.
[0083] Example 2: Norepinephrine release in the prefrontal cortex
[0084] Histamine H3 receptor antagonists / inverse agonists (JSLin et al., Neurobiology of Disease, 2008, 30, 74; G. Flik et al., Journal of Molecular Neuroscience, 2015, 56, 320) and norepinephrine reuptake inhibitors (FPBymaster et al., Current Pharmaceutical Design, 2005, 11, 1475; FPBymaster et al., Neuropsychopharmacology, 2002, 27, 699) are known to enhance extracellular norepinephrine in the prefrontal cortex and reflect activation of noradrenergic neurotransmission. However, in both cases, the enhancement is limited.
[0085] As described by A.D. Edhurst et al. (Journal of Pharmacology & Experimental Therapeutics, 2007, 321, 1032-1045) and G. Flik et al. (Journal of Molecular Neuroscience, 2015, 56, 320-328), the effect of microdialysis on norepinephrine release in the prefrontal cortex was investigated in vivo in live male Wistar rats. Briefly, anesthetized rats were implanted with a guiding cannula for sampling in the prefrontal cortex. At least one week after surgery, a microdialysis probe was inserted into the guiding cannula and continuously perfused with artificial cerebrospinal fluid (CSF). Rats were acclimatized to the microdialysis cage for approximately 3 hours. Rats were then orally (orally) administered a carrier, drug, or combination of drugs. Norepinephrine content in CSF samples collected every 30 minutes was analyzed by HPLC coupled with electrochemical detection. Norepinephrine sample levels were expressed as a percentage of basal norepinephrine release recorded 1.5 hours prior to carrier or drug treatment.
[0086] Surprisingly, when the two types of compounds were combined, the activation of norepinephrine neurotransmission in the prefrontal cortex was enhanced in a synergistic manner, as shown in the following data and Figure 5 As shown:
[0087]
[0088] Therefore, the combination of the two types of compounds can allow for a reduction in the dosage of each component, thereby enhancing tolerability.
Claims
1. A composition of an H3 antagonist or inverse agonist with an antidepressant selected from norepinephrine reuptake inhibitors, wherein the H3 antagonist or inverse agonist is teloprecin of the following formula or any pharmaceutically acceptable salt thereof: The norepinephrine reuptake inhibitor is selected from duloxetine, reboxetine, and atoxetine. wherein The amounts of teloprene and the antidepressant are such that the composition, when administered to a patient, exhibits a synergistic effect with respect to at least one of (a) an increase in resting wakefulness duration and (b) a decrease in REM sleep duration.
2. The composition of claim 1, wherein, The H3 antagonist or inverse agonist hydrochloride salt of Formula (I).
3. The composition of claim 1 which is or a pharmaceutically acceptable salt thereof in combination with duloxetine.
4. A pharmaceutical composition comprising the composition according to any one of claims 1 to 3, wherein, The two components can be administered simultaneously, separately, or alternately over time.
5. Use of the composition according to any one of claims 1-3 in the preparation of a medicament for treating and / or preventing excessive daytime sleepiness in patients with insufficient norepinephrine release.
6. Use according to claim 5, wherein, The condition is excessive daytime sleepiness and occurs in patients with the following conditions: - Narcolepsy with or without cataplexy, - Idiopathic hypersomnia, - Daytime narcolepsy -Obstructive sleep apnea, -Circadian rhythm sleep-wake disorder - Parkinson's disease, or -P-Weiss syndrome.
7. The use according to claim 5, wherein, The condition is excessive daytime sleepiness and occurs in patients with depression.
8. The application according to claim 5, wherein, The dosage of telolide is 5-40 mg / day, the dosage of duloxetine is 20-120 mg / day, the dosage of atoxetine is 10-100 mg / day, and the dosage of reboxetine is 2-12 mg / day.
Citation Information
Patent Citations
Novel histamine h3-receptor ligands and their therapeutic applications
WO2006117609A2
